ArticleEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists2026
Implications of Expanded Advanced Fibrosis Screening Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease in Primary Care.
Article in Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveAdvanced fibrosis is associated with cirrhosis, cancer, and mortality in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Since MASLD is underdiagnosed in primary care, and diabetes mellitus type 2 (T2DM) is strongly associated with MASLD, the 2024 American Diabetes Association guidelines recommend screening for advanced fibrosis in patients with T2DM and prediabetes using the Fibrosis-4 Index (FIB-4). We aimed to determine the proportion of primary care patients with T2DM and prediabetes who had FIB-4s at risk for advanced fibrosis and required confirmatory testing.
methodsThis cross-sectional study evaluated primary care patients with T2DM or prediabetes and a FIB-4 score between 2022 and 2024. The outcome of interest was a FIB-4 score in need of confirmatory fibrosis risk assessment. Univariate analyses were used to describe the cohort. Logistic regression models evaluated the association between T2DM and a FIB-4 score at indeterminate risk or greater for advanced fibrosis.
resultsOf 8366 patients with T2DM and prediabetes, 2064 (25%) had FIB-4s in need of confirmatory risk assessment. The expanded FIB-4 fibrosis screening for T2DM and prediabetes increased the number of patients needing confirmatory fibrosis risk assessment by 9.1 times compared to those with diagnoses of MASLD (n = 228). Further, patients with T2DM were not more likely to have an indeterminate risk or greater FIB-4 (odds ratio: 0.86; 95% CI: 0.77-0.96) compared to those with prediabetes in the fully adjusted model.
conclusionExpanded screening for advanced liver fibrosis would substantially increase the number of patients who need confirmatory testing for liver fibrosis, increasing cost and straining access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.